The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Radioimmunotherapy Market Research Report 2025
Synopsis
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Radioimmunotherapy market was valued at US$ 1042.8 million in 2023 and is anticipated to reach US$ 4477.8 million by 2030, witnessing a CAGR of 17.4% during the forecast period 2024-2030.
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.
This report aims to provide a comprehensive presentation of the global market for Radioimmunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioimmunotherapy.
Report Scope
The Radioimmunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radioimmunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radioimmunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Segment by Type
Beta-emitting
Targeted Alpha Therapy
Segment by Application
Solid Tumor
Non Hodgkin Lymphoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radioimmunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Radioimmunotherapy market was valued at US$ 1042.8 million in 2023 and is anticipated to reach US$ 4477.8 million by 2030, witnessing a CAGR of 17.4% during the forecast period 2024-2030.
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.
This report aims to provide a comprehensive presentation of the global market for Radioimmunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioimmunotherapy.
Report Scope
The Radioimmunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radioimmunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radioimmunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Segment by Type
Beta-emitting
Targeted Alpha Therapy
Segment by Application
Solid Tumor
Non Hodgkin Lymphoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radioimmunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market by Application
1.3.1 Global Radioimmunotherapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2019-2030)
2.2 Radioimmunotherapy Growth Trends by Region
2.2.1 Global Radioimmunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Radioimmunotherapy Historic Market Size by Region (2019-2024)
2.2.3 Radioimmunotherapy Forecasted Market Size by Region (2025-2030)
2.3 Radioimmunotherapy Market Dynamics
2.3.1 Radioimmunotherapy Industry Trends
2.3.2 Radioimmunotherapy Market Drivers
2.3.3 Radioimmunotherapy Market Challenges
2.3.4 Radioimmunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioimmunotherapy Players by Revenue
3.1.1 Global Top Radioimmunotherapy Players by Revenue (2019-2024)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioimmunotherapy Revenue
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2023
3.5 Radioimmunotherapy Key Players Head office and Area Served
3.6 Key Players Radioimmunotherapy Product Solution and Service
3.7 Date of Enter into Radioimmunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioimmunotherapy Breakdown Data by Type
4.1 Global Radioimmunotherapy Historic Market Size by Type (2019-2024)
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2025-2030)
5 Radioimmunotherapy Breakdown Data by Application
5.1 Global Radioimmunotherapy Historic Market Size by Application (2019-2024)
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Radioimmunotherapy Market Size (2019-2030)
6.2 North America Radioimmunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Radioimmunotherapy Market Size by Country (2019-2024)
6.4 North America Radioimmunotherapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radioimmunotherapy Market Size (2019-2030)
7.2 Europe Radioimmunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Radioimmunotherapy Market Size by Country (2019-2024)
7.4 Europe Radioimmunotherapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioimmunotherapy Market Size (2019-2030)
8.2 Asia-Pacific Radioimmunotherapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Radioimmunotherapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Radioimmunotherapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radioimmunotherapy Market Size (2019-2030)
9.2 Latin America Radioimmunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Radioimmunotherapy Market Size by Country (2019-2024)
9.4 Latin America Radioimmunotherapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioimmunotherapy Market Size (2019-2030)
10.2 Middle East & Africa Radioimmunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Radioimmunotherapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Radioimmunotherapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Radioimmunotherapy Introduction
11.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Radioimmunotherapy Introduction
11.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Lantheus
11.3.1 Lantheus Company Detail
11.3.2 Lantheus Business Overview
11.3.3 Lantheus Radioimmunotherapy Introduction
11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024)
11.3.5 Lantheus Recent Development
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Detail
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Radioimmunotherapy Introduction
11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024)
11.4.5 Aurobindo Pharma Recent Development
11.5 Mundipharma
11.5.1 Mundipharma Company Detail
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Radioimmunotherapy Introduction
11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024)
11.5.5 Mundipharma Recent Development
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Detail
11.6.2 China Isotope & Radiation Business Overview
11.6.3 China Isotope & Radiation Radioimmunotherapy Introduction
11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024)
11.6.5 China Isotope & Radiation Recent Development
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Detail
11.7.2 Curium Pharmaceuticals Business Overview
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Introduction
11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.7.5 Curium Pharmaceuticals Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Detail
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Radioimmunotherapy Introduction
11.8.4 Gilead Sciences Revenue in Radioimmunotherapy Business (2019-2024)
11.8.5 Gilead Sciences Recent Development
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Detail
11.9.2 Clarity Pharmaceuticals Business Overview
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
11.9.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.9.5 Clarity Pharmaceuticals Recent Development
11.10 Curasight
11.10.1 Curasight Company Detail
11.10.2 Curasight Business Overview
11.10.3 Curasight Radioimmunotherapy Introduction
11.10.4 Curasight Revenue in Radioimmunotherapy Business (2019-2024)
11.10.5 Curasight Recent Development
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Detail
11.11.2 Nordic Nanovector Business Overview
11.11.3 Nordic Nanovector Radioimmunotherapy Introduction
11.11.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2019-2024)
11.11.5 Nordic Nanovector Recent Development
11.12 Philogen
11.12.1 Philogen Company Detail
11.12.2 Philogen Business Overview
11.12.3 Philogen Radioimmunotherapy Introduction
11.12.4 Philogen Revenue in Radioimmunotherapy Business (2019-2024)
11.12.5 Philogen Recent Development
11.13 RadioMedix
11.13.1 RadioMedix Company Detail
11.13.2 RadioMedix Business Overview
11.13.3 RadioMedix Radioimmunotherapy Introduction
11.13.4 RadioMedix Revenue in Radioimmunotherapy Business (2019-2024)
11.13.5 RadioMedix Recent Development
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Detail
11.14.2 Telix Pharmaceuticals Business Overview
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
11.14.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.14.5 Telix Pharmaceuticals Recent Development
11.15 Orano Med
11.15.1 Orano Med Company Detail
11.15.2 Orano Med Business Overview
11.15.3 Orano Med Radioimmunotherapy Introduction
11.15.4 Orano Med Revenue in Radioimmunotherapy Business (2019-2024)
11.15.5 Orano Med Recent Development
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Detail
11.16.2 Actinium Pharmaceuticals Business Overview
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Introduction
11.16.4 Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.16.5 Actinium Pharmaceuticals Recent Development
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Detail
11.17.2 Y-mAbs Therapeutics Business Overview
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Introduction
11.17.4 Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2019-2024)
11.17.5 Y-mAbs Therapeutics Recent Development
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Detail
11.18.2 Fusion Pharmaceuticals Business Overview
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Introduction
11.18.4 Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.18.5 Fusion Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
